- Biosensors International
Infobox_Company
company_name = Biosensors International Group, Ltd.
company_| company_type = Public (sgx|B20)
company_slogan = "Improving Lives Through Medical Innovation"
headquarters = Singapore
key_people =Lu Yoh-Chie , Chairman and CEO
industry =Medical technology
revenue = USD $37.8 Million (2006)
products =Medical devices
foundation = unknown
homepage = [http://www.biosensorsintl.com/ www.biosensorsintl.com]Biosensors International Group (sgx|B20) is a medical device company that specializes in developing, manufacturing and licensing technologies for use in interventional cardiology procedures and critical care. The company has manufacturing facilities in Singapore and The Netherlands, and it operates R&D centres in the United States. In May 2005, the company was listed in the Mainboard of the Singapore Exchange (
SGX ).To enter the China market, Biosensors have set up a joint-venture with Hong Kong listed Shandong Weigao to market and distribute coronary stents in China. [ Unknown. [http://www.listedcompany.com/ir/biosensors/newsroom/Biosensors_Weigao.pdf Biosensors and Weigao Sign Letter of Intent and Expand Business Collaboration] , "Biosensors Investor Relations"]
As one of the few companies with proprietary
drug-eluting stent technology, Biosensors also obtains revenues through licensing its technologies to other medical device companies likeTerumo ,Guidant , and specialty-stent providers like Devax, Inc. and Xtent, Inc.Biosensors' new stent technologies includes the BioMatrix drug-eluting stent which utilizes a proprietary biodegradable polymer and
Biolimus A9 drug on its S-Stent platform. Clinical trials are still undergoing at the moment though the company is confident that it will obtain CE Mark approval for this product.See also
Drug-eluting stent External links
* [http://www.biosensorsintl.com Biosensors International Website]
Notes
Wikimedia Foundation. 2010.
